-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Raised to $64; RBC Capital: 'We see opportunity for share appreciation'
-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Lowered to $62 at RBC Capital; 'Shares Should Rebound in 2026'
-
-
-
-
-
-
-
Raymond James on Legend Biotech Corp. (LEGN): 'Arcellx Takeout Indicates Legend is Hugely Undervalued'
-
-
-
-
-
-
-
Legend Biotech (LEGN) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Cantor Fitzgerald Starts Legend Biotech Corp. (LEGN) at Overweight
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Legend Biotech (LEGN) Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting
-
416,464 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

